Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP420352.RADINUR7DF_FKBZuVv5fRTB31zmLYGJP95ny6uqamwG8s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP420352.RADINUR7DF_FKBZuVv5fRTB31zmLYGJP95ny6uqamwG8s130_assertion type Assertion NP420352.RADINUR7DF_FKBZuVv5fRTB31zmLYGJP95ny6uqamwG8s130_head.
- NP420352.RADINUR7DF_FKBZuVv5fRTB31zmLYGJP95ny6uqamwG8s130_assertion description "[Randomized clinical studies investigating the clinical benefits of farnesyltransferase inhibition, with or without a taxane and trastuzumab, in patients with treatment-naive HER2-positive metastatic breast carcinoma are now warranted.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP420352.RADINUR7DF_FKBZuVv5fRTB31zmLYGJP95ny6uqamwG8s130_provenance.
- NP420352.RADINUR7DF_FKBZuVv5fRTB31zmLYGJP95ny6uqamwG8s130_assertion evidence source_evidence_literature NP420352.RADINUR7DF_FKBZuVv5fRTB31zmLYGJP95ny6uqamwG8s130_provenance.
- NP420352.RADINUR7DF_FKBZuVv5fRTB31zmLYGJP95ny6uqamwG8s130_assertion SIO_000772 14613029 NP420352.RADINUR7DF_FKBZuVv5fRTB31zmLYGJP95ny6uqamwG8s130_provenance.
- NP420352.RADINUR7DF_FKBZuVv5fRTB31zmLYGJP95ny6uqamwG8s130_assertion wasDerivedFrom befree-2016 NP420352.RADINUR7DF_FKBZuVv5fRTB31zmLYGJP95ny6uqamwG8s130_provenance.
- NP420352.RADINUR7DF_FKBZuVv5fRTB31zmLYGJP95ny6uqamwG8s130_assertion wasGeneratedBy ECO_0000203 NP420352.RADINUR7DF_FKBZuVv5fRTB31zmLYGJP95ny6uqamwG8s130_provenance.